Heart Failure Hospitalization and Mortality in Cardiac Amyloidosis

For patients with transthyretin cardiac amyloidosis (TTR-CA), heart failure hospitalization (HFH) often marks a critical inflection point—one that carries prognostic weight beyond what conventional biomarkers and imaging can convey. While clinicians routinely track troponin levels, NT-proBNP, and echocardiographic parameters, the clinical significance of an actual hospitalization event remains less defined.

A multicenter international registry study published in ESC Heart Failure examined whether HFH functions as an independent mortality predictor, even after accounting for established risk markers.

What the International Cohort Revealed

The analysis followed 654 patients from a multicenter TTR-CA registry, tracking outcomes based on whether they experienced at least one HFH. The cohort skewed older (median age 78 years) with predominantly wild-type disease (70%). Over a median follow-up of 24 months, roughly one in five patients was hospitalized for heart failure, and one in four died.

The patients who landed in the hospital painted a picture of more advanced disease from the start. They were older by six years on average (82 vs 76), carried a higher burden of wild-type TTR-CA (89% vs 66%), and had more symptomatic presentations; 87% were in New York Heart Association Class II-IV compared with 62% of those who stayed out of the hospital.

Perhaps most striking, fewer HFH patients were receiving disease-modifying therapy (32% vs 47%), raising questions about potential undertreatment in those who might benefit most.

Biomarkers and Imaging Tell the Same Story

The biomarker profiles underscored the severity gap. Patients who experienced HFH showed significantly worse kidney function (eGFR 53 vs 69 ml/min/1.73 m²) and markedly elevated cardiac stress markers. Median NT-proBNP levels were more than four times higher in the HFH group (4,051 vs 910 pg/ml), and troponin followed suit. National Amyloidosis Centre disease staging reinforced the pattern: 41% of HFH patients fell into Stage III, the highest risk category, compared with just 10% of those without hospitalization.

Echocardiography filled in the structural details. Beyond thicker left ventricular walls, HFH patients demonstrated reduced stroke volume, impaired global longitudinal strain suggesting early systolic dysfunction, elevated E/e' ratios pointing to diastolic dysfunction, and more frequent significant valvular disease. Right ventricular function was similarly compromised. This constellation suggests that hospitalization captures a patient population in whom the disease has already imposed widespread cardiac damage.

The Mortality Signal: Nearly Eightfold Risk

When investigators examined all-cause mortality using time-dependent analysis to account for when HFH occurred, the association proved both powerful and persistent. HFH conferred a 7.71-fold increased risk of death (95% CI 5.50-10.82) in univariable analysis. Even after adjusting for clinical variables, biomarkers including eGFR and NAC disease stage, and echocardiographic metrics like left ventricular mass, stroke volume, and E/e' ratio, HFH retained its prognostic strength.

This magnitude of association suggests HFH represents more than just a reflection of baseline severity. It may signify a tipping point—a moment when compensatory mechanisms fail and the disease trajectory accelerates toward worse outcomes.

Limitations Worth Noting

The retrospective design leaves some clinical questions unanswered. The study couldn't capture what triggered each hospitalization, how patients were managed during admission, or whether treatment approaches varied across centers. Understanding these factors prospectively could identify modifiable elements—specific precipitants to avoid or interventions that might alter post-hospitalization trajectories. Standardized HFH management protocols and prospective data collection would strengthen future investigations.

Clinical Implications for Practice

For clinicians managing TTR-CA, this study delivers a clear message: heart failure hospitalization demands immediate prognostic reassessment. The event should trigger reevaluation of disease-modifying therapy—particularly for patients not yet on treatment—optimization of heart failure management, and potentially earlier consideration of advanced therapies. The data suggest there’s a window before hospitalization when intervening with disease-modifying treatment might alter the course.

HFH also serves as a valuable risk stratification tool in itself. In discussions with patients and families about prognosis, it provides a concrete clinical milestone that carries measurable weight. Rather than viewing hospitalization as simply a setback, clinicians might frame it as a signal for treatment intensification and closer monitoring—a moment to recalibrate both therapy and expectations in this progressive disease.

Reference
Laenens D, Debonnaire P, De Smet MAJ, et al. Prognostic value of heart failure hospitalization in transthyretin cardiac amyloidosis: an international cohort study. ESC Heart Fail. 2026;13(1):xvaf013. doi:10.1093/eschf/xvaf013